| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.03M | $4.47M | $459K | $23.7M | $41.9M | $44.5M | $35.4M | $24.2M | $19.5M | $19.2M |
| Revenue growth | — | 120.3% | -89.7% | 5051.8% | 77.1% | 6.2% | -20.4% | -31.8% | -19.3% | -1.5% |
| Gross profit | $413K | $3.12M | $355K | $14.5M | $26.4M | $30.0M | $22.3M | $15.0M | $12.0M | $12.0M |
| Gross margin | 20.3% | 69.7% | 77.3% | 61.4% | 63.0% | 67.4% | 63.1% | 62.0% | 61.6% | 62.4% |
| Operating income | -$3.89M | -$1.36M | -$1.80M | -$14.8M | -$17.6M | -$19.6M | -$78.3M | -$22.5M | -$3.32M | -$2.16M |
| Operating margin | -191.4% | -30.4% | -391.4% | -62.6% | -42.0% | -44.1% | -221.1% | -93.1% | -17.0% | -11.3% |
| Net income | -$3.90M | -$1.39M | $62.8K | -$51.4M | $12.6M | -$23.4M | -$70.1M | -$22.9M | -$3.70M | -$2.04M |
| Net margin | -191.8% | -31.0% | 13.7% | -217.1% | 30.1% | -52.6% | -198.0% | -95.0% | -19.0% | -10.6% |
| EPS (diluted) | -$1.13 | -$0.38 | $0.00 | $0.00 | $0.28 | -$0.47 | -$55.80 | -$13.32 | -$14.29 | -$1.09 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.90M | -$2.33M | -$5.57M | -$15.4M | -$10.7M | -$14.1M | -$15.0M | -$4.30M | -$353K | -$1.45M |
| Capital expenditures | $127K | $7.97K | $23.6K | $1.20M | $1.32M | $342K | $689K | $298K | $190K | $184K |
| Free cash flow | -$3.02M | -$2.34M | -$5.60M | -$16.6M | -$12.0M | -$14.4M | -$15.7M | -$4.60M | -$543K | -$1.64M |
| Dividends paid | — | — | — | $0.00 | $367K | $2.55M | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.3K | $284K | $4.28M | $4.69M | $14.8M | $26.4M | $6.72M | $1.80M | $2.45M | $2.26M |
| Total assets | $1.62M | $7.07M | $15.0M | $94.5M | $111M | $125M | $40.8M | $16.2M | $10.6M | $10.4M |
| Total liabilities | $1.92M | $1.92M | $998K | $56.9M | $31.7M | $21.7M | $9.37M | $7.16M | $8.62M | $3.19M |
| Long-term debt | — | — | — | — | $264K | $109K | $125K | $9.00 | — | — |
| Shareholders' equity | $363K | $4.21M | $14.0M | $37.6M | $79.2M | $103M | $31.4M | $9.03M | $1.96M | $7.23M |
| Retained earnings | -$4.49M | -$6.26M | -$6.67M | -$59.6M | -$47.4M | -$73.3M | -$147M | -$174M | -$182M | -$179M |
| Shares (wtd avg diluted) | 3.40M | 5.79M | 7.75M | 17.9M | 45.2M | 54.9M | 1.33M | 2.02M | 539K | 4.02M |
Every figure is extracted from cbdMD, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.